Practice
Open Access
Allopurinol hypersensitivity syndrome
Wid Yaseen, Bourne Auguste and Jonathan Zipursky
CMAJ April 03, 2023 195 (13) E483; DOI: https://doi.org/10.1503/cmaj.221575
Wid Yaseen
Department of Medicine (Yaseen, Auguste, Zipursky), University of Toronto; Divisions of Nephrology (Auguste), and Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre, Toronto, Ont.
MDBourne Auguste
Department of Medicine (Yaseen, Auguste, Zipursky), University of Toronto; Divisions of Nephrology (Auguste), and Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre, Toronto, Ont.
MD MScJonathan Zipursky
Department of Medicine (Yaseen, Auguste, Zipursky), University of Toronto; Divisions of Nephrology (Auguste), and Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre, Toronto, Ont.
MD PhDArticle Figures & Tables
There are no figures or tables available.
In this issue
Article tools
Allopurinol hypersensitivity syndrome
Wid Yaseen, Bourne Auguste, Jonathan Zipursky
CMAJ Apr 2023, 195 (13) E483; DOI: 10.1503/cmaj.221575
Jump to section
- Article
- Allopurinol hypersensitivity syndrome (AHS) is a severe adverse drug reaction
- Guidelines recommend screening for the HLA-B*58:01 allele in high-risk populations before starting allopurinol
- Chronic kidney disease and cardiovascular disease are clinical risk factors for AHS
- Starting low-dose allopurinol and titrating slowly might mitigate the risk of AHS
- Treatment includes stopping allopurinol and supportive care
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.
Podcast